The hedge fund’s shares of CHS are valued at $496,037. CHS makes up about 0.22 percent of Palouse Capital’s portfolio, according to Founders Daily.
Other hedge funds, including Dupont Capital Management, also reduced their stakes in CHS in the most recent quarter.
More articles on healthcare finance:
Fitch: Clinton’s healthcare plan could benefit hospitals in the near term, but long-term effects uncertain
CMS makes offer to clear Medicare appeals backlog: 6 things to know
UPMC operating margin shrinks in Q1
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.